US20160039932A1 - Monoclonal antibodies with specificity for fetal erythroid cells - Google Patents
Monoclonal antibodies with specificity for fetal erythroid cells Download PDFInfo
- Publication number
- US20160039932A1 US20160039932A1 US14/825,516 US201514825516A US2016039932A1 US 20160039932 A1 US20160039932 A1 US 20160039932A1 US 201514825516 A US201514825516 A US 201514825516A US 2016039932 A1 US2016039932 A1 US 2016039932A1
- Authority
- US
- United States
- Prior art keywords
- cells
- fetal
- antibody
- antigen
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70582—CD71
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25125—Digestion or removing interfering materials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
Definitions
- lymphocytes lymphocytes
- trophoblasts trophoblasts
- NRBCs nucleated red blood cells
- Fetal lymphocytes have been detected still one to 5 years after childbirth. This longevity may interfere with the accurate diagnosis in following pregnancies.
- Trophoblasts are attractive targets because they can be easily identified by their morphology. However, they can not be easily used for diagnostic purposes, because as placental cells they might differ from cells of the fetus: in about 1% of diagnosed chromosomal aberrations in trophoblasts the fetus turned out to be healthy.
- NRBCs Fetal nucleated red blood cells
- NRBCs Fetal nucleated red blood cells
- NRBCs Fetal nucleated red blood cells
- They are identified through a marker profile, which is characteristic for erythroid precursor cells and which is different from other blood cell subpopulations.
- Blood cells are extensively characterized by so-called clusters of differentiation (CD) markers as defined at the 7th Workshop and Conference on Human Leukocyte Differentiation Antigens (Harrogate 2000). Immature erythroid cells express CD71 and they lack CD45 which is expressed on leukocytes. This knowledge can be used to distinguish erythroid precursor cells from other mononuclear cells.
- fetal cells In order to isolate and identify fetal cells (1 amongst 10 5 to 10 7 maternal nucleated cells) most stringent criteria have to be met. There is no cell surface marker available yet which is exclusively expressed on fetal NRBCs. For the enrichment of fetal cells usually immunomagnetic or flow cytometric cell separation techniques are used either alone or in combination. The results of the chromosomal or genetic analysis of the isolated cells have been compared with the results obtained with amniotic cells. Many investigations have shown the technical feasibility of the non-invasive approach with large cohorts.
- fetal NRBCs can only be achieved by the recognition of a marker, which is preferentially expressed on fetal erythroid cells or which is expressed or localized in a way that is specific for fetal cells within the blood.
- the objective of this invention is the generation of antibodies, which allow the discrimination between fetal and adult erythroid cells and the unambiguous identification of fetal cells.
- Fetal cells recognized by these antibodies preferably should possess at least in part an intact cell nucleus, express the CD71 antigen and should miss the CD45 antigen in line with previously published results.
- the object of the invention is the generation of monoclonal antibodies, which react specifically with fetal cells as well as a hybridoma cell line, which produces such antibodies.
- This object is solved by the antibody according to embodiment 1, 7 or 10, the antigen according to claim 9 and the hybridoma cell according to embodiment 4 or 5. Further improvements of the antibodies, the hybridoma cell and the antigen are given in the embodiments 2-6, 8, and 11-16.
- Monoclonal antibody reacting with a surface antigen present on fetal red blood cells including their nucleated precursor cells, but not with surface antigens on adult erythroid cells.
- Antibody according to embodiment 1 characterized in that it reacts with most or all fetal erythroid cells, which express the CD71 antigen but are negative for CD45 antigen expression.
- Antibody according to embodiment 1 or 2 characterized in that it reacts with fetal erythroid cells but not with the CD71 antigen.
- Hybridoma cell producing monoclonal antibodies according to one of the preceding embodiments.
- Hybridoma cell as deposited under accession number DSM ACC 2666 on Jul. 13, 2004 at the Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH in Braunschweig, Germany.
- Hybridoma cell according to embodiments 4 and 5.
- Antibody characterized in that it recognizes or binds specifically to a surface antigen according to embodiment 9.
- Method for detection or identification of fetal cells in a sample characterized by labeling said fetal cells by an antibody according to one of embodiments 1 to 3, 7, 8, or 10.
- sample is maternal blood or a sample of maternal blood.
- mice have been immunized with isolated erythroid cells from cord blood (CD71+, CD45 ⁇ ), which carried the “i” antigen as defined by the autoantibody described in DE 100 35 433 A1.
- the immunization with these cells opens the possibility that besides antibodies against the “i” antigen also antibodies with specificities against new markers could be generated, which could be used to identify erythroid precursor cells.
- the spleen cells of the immunized mice were fused with a myeloma cell line to produce hybridomas according to standard procedures (Schetters H, Production of Monoclonal Antibodies, in: Methods of Immunological Analysis, Masseyeff R F, Albert W H and Staines N A (Eds.) Vol. 2, Ch. 4.3, 230-245, VCH Weinheim, 1993).
- FIG. 1A is a diagram of the light scatter properties of erythroid precursor cells.
- FIG. 1B is a diagram of fluorescence properties of the cells in region R1 and labeled with CD71-antibody and dye LDS751 labeling all nuclei.
- FIG. 1C is a diagram of fluorescence properties of cells in region R2 incubated with CD71 antibodies.
- FIG. 1D is a diagram of fluorescence properties of the cells in region R2.
- FIG. 2 is a graph showing the absorption of monoclonal antibodies 4B8 and 4B9 with adult erythrocytes, followed by the determination of their binding capability on cord blood cells.
- FIG. 3A is histogram showing unstained, negative cord blood cells marked as “unlabeled” and cord blood cells incubated with labeled antibodies 4B8 and 4B9.
- FIG. 3B is a histogram of the adult blood cells showing the same fluorescence intensity (x-axes), whether they are incubated as antibodies, 4B8, 4B9, or with no antibodies.
- FIG. 4 A 1 - 4 B 2 shows the immunofluorescent and immunoenzymatic analyses of fetal blood cells.
- FIG. 4 A 1 and FIG. 4 B 1 show the original fluorescence picture and
- FIG. 4 A 2 and FIG. 4 B 2 show schematic drawings of FIG. 4 A 1 and FIG. 4 B 1 , respectively.
- mice were immunized with flow sorted human cord blood cells (CD71+, antigen-i+, CD19 ⁇ and CD45 ⁇ ).
- Hybridoma supernatants were screened on pooled mononuclear cord blood cells, whereas the corresponding amount of erythroid precursors was determined by cytochemical staining of blood smears.
- cytochemical staining of blood smears For the hybridoma screening a six-parameter flow cytometric analysis (four colours, forward and side scatter) was set up for the simultaneous identification of erythroid precursor cells, leukocytes, enucleated erythrocytes and for antibodies reacting specifically with fetal cells.
- immunohistochemical analyses have been performed with fetal blood smears and fetal liver sections from the 6th up to 38th week of gestation as well as with adult blood, normal adult bone marrow and adult erythrocytes as controls.
- a clone (accession number DSM ACC 2666 at the Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH (DSMZ)) with specificity for a surface antigen exclusively expressed on fetal erythroid cells has been identified.
- the new antibody showed unaltered binding to erythroid cells from fetal blood of early times of gestation (6th week) up to childbirth. Moreover, detailed examinations showed no surface reactivity with adult erythrocytes, erythroblasts or lymphatic and myeloid cells. This antibody did not react with cells of fetal haemolymphatic organs.
- the new monoclonal antibody binds specifically fetal erythroid cells and thus can differentiate between fetal and adult red blood cells. Because of the expression of this fetal antigen in early stages of gestation a noninvasive prenatal diagnostic may be feasible. This antibody can be applied for different enrichment techniques and/or for the identification of fetal erythroid cells.
- FITC fluorescent dye
- the identification of the erythroid precursor cells is possible due to their light scatter characteristics and by their binding of phycoerythrin labeled CD71 specific antibodies (CD71 PE, Diatec, cat#3212). Leukocytes could be discerned by their binding to allophycocyanin labeled CD45 specific antibodies (CD45 APC, BD Pharmingen, cat#555485). Nucleated and enucleated erythroid cells can be distinguished by their binding or absence of binding of the nucleic acid dye. With this procedure it is possible to identify antibodies binding to the intended target cells, i.e. fetal NRBCs, without cross-reaction towards adult erythrocytes or leukocytes ( FIG. 1 ).
- Blood group antigens can be found on adult erythrocytes and their precursors in large amounts. Therefore, they might induce a major immune response when used as antigens. Antibodies against these blood group antigens are not suitable for the identification of fetal cells. In order to exclude antibodies binding to antigens on adult erythrocytes including blood group antigens, their binding specificity towards fetal cells is investigated after absorption on erythrocytes. Erythrocyte with the blood group AB Rh+ have been harvested and stabilized with a reagent supplied by Meridian Diagnostics Europe, Bad Homburg. The antibodies under investigation have been incubated with increasing numbers of erythrocytes and tested before and afterwards for their binding activity for target cells.
- Hybridoma clone producing a monoclonal antibody of the IgM isotype showing the required binding characteristics in the screening procedure could be identified. It has the designation 4B9 and was deposited by the applicant of the present patent or patent application on Jul. 13, 2004 at the Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH (DSMZ, Braunschweig) under the accession number DSM ACC 2666. A second antibody 4B8 recognizing the same epitope is mentioned in FIGS. 2 and 3 .
- Monoclonal antibody of identical isotype or murine hyper-immune serum Monoclonal antibody of identical isotype or murine hyper-immune serum.
- Antibodies generated with the immunization strategy used may be directed against CD71. To exclude these antibodies, analyses were performed that show whether CD71-antibodies compete for the same binding site. Biotinylated antibody 4B8 was preincubated with mononuclear cells from cord blood. Then unlabeled CD71-specific antibody (Anti-CD71, Clone DF1513, DPC Biermann, Bad Nauheim, Germany) was added. After streptavidin-DTAF-labeling it was analyzed by flow cytometry whether CD71-antibodies had replaced the antibody 4B8. As a positive control sample for this competition experiment, unlabeled antibody 4B8 was added instead of CD71. These analyses showed that antibodies 4B8 and CD71 do not compete for the same epitope whereas the addition of unlabeled antibody 4B8 had diminished the signal.
- FIGS. 1 to 4 are described in detail
- FIG. 1 A first figure.
- Mononuclear cord blood cells were stained with labeled antibodies (anti CD45, anti CD71 and the antibody under investigation, 4B9) and a DNA dye. Antibody binding was measured with a flow cytometer.
- FIG. 2 discloses absorption of monoclonal antibodies 4B8 and 4B9 with adult erythrocytes, followed by the determination of their binding capability on cord blood cells. It is shown that neither 4B8 antibody nor 4B9 antibody is absorbed by adult red blood cells. For positive and negative controls antibodies against CD71 and glycophorin A were used.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ecology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
- This application is a division of U.S. application Ser. No. 14/028,027, filed Sep. 16, 2013, which is a continuation of U.S. application Ser. No. 12/979,535, filed Dec. 28, 2010, now U.S. Pat. No. 8,536,312, issued Sep. 17, 2013, which is a division of U.S. application Ser. No. 10/599,512, now U.S. Pat. No. 7,858,757, issued Dec. 28, 2010, which is a national stage application of international application No. PCT/EP2005/003371, filed Mar. 31, 2005, which claims priority to European application no. 04007811.5 filed Mar. 31, 2004, the contents of each of which are incorporated by reference herein in their entireties.
- Social developments led to an increase of prenatal investigations. Amniocentesis or less frequently sampling of chorionic villi is performed in every tenth pregnancy for the prenatal analysis of, e.g. trisomy 21. The risk for a chromosomal defect increases with the age of the mother. This is why amniocentesis is performed in more than 50% of pregnant women aged 35 years or older. However, most children with chromosomal or genetic defects are still born by women under the age of 35, if the total number is taken into account. The probability for a trisomy 21 is 0.3% in fetuses of women aged 35 years and older. This has to be seen in the context of a 0.5% risk to induce an abortion by the amniocentesis procedure. From these numbers it is obvious that there is a great need for an alternative diagnostic procedure which yields the same results without bearing a risk for the unborn. One approach could be the isolation of fetal cells from maternal blood. This would eliminate risks for the fetus.
- It was estimated that one fetal cell can be found in 105 to 107 maternal nucleated blood cells. Further investigations have shown, that in the presence of chromosomal aberrations more fetal cells can be detected in the maternal circulation. This raises the chance to detect an aneuploid fetus by non-invasive procedures.
- Three different types of fetal cells have been identified in maternal blood: lymphocytes, trophoblasts and nucleated red blood cells (NRBCs).
- Fetal lymphocytes have been detected still one to 5 years after childbirth. This longevity may interfere with the accurate diagnosis in following pregnancies.
- Trophoblasts are attractive targets because they can be easily identified by their morphology. However, they can not be easily used for diagnostic purposes, because as placental cells they might differ from cells of the fetus: in about 1% of diagnosed chromosomal aberrations in trophoblasts the fetus turned out to be healthy.
- Fetal nucleated red blood cells (NRBCs) appear early in the maternal circulation, however do not persist after birth. Since they have a nucleus they are preferred candidates for chromosomal analysis. However, up to now they can not be distinguished easily and unambiguously from other blood cells. They are identified through a marker profile, which is characteristic for erythroid precursor cells and which is different from other blood cell subpopulations. Blood cells are extensively characterized by so-called clusters of differentiation (CD) markers as defined at the 7th Workshop and Conference on Human Leukocyte Differentiation Antigens (Harrogate 2000). Immature erythroid cells express CD71 and they lack CD45 which is expressed on leukocytes. This knowledge can be used to distinguish erythroid precursor cells from other mononuclear cells.
- In order to isolate and identify fetal cells (1 amongst 105 to 107 maternal nucleated cells) most stringent criteria have to be met. There is no cell surface marker available yet which is exclusively expressed on fetal NRBCs. For the enrichment of fetal cells usually immunomagnetic or flow cytometric cell separation techniques are used either alone or in combination. The results of the chromosomal or genetic analysis of the isolated cells have been compared with the results obtained with amniotic cells. Many investigations have shown the technical feasibility of the non-invasive approach with large cohorts.
- However, the existing procedures are still not suitable for routine diagnosis. It has to be assured that the cells under investigation are unambiguously fetal cells. The identification of fetal NRBCs can only be achieved by the recognition of a marker, which is preferentially expressed on fetal erythroid cells or which is expressed or localized in a way that is specific for fetal cells within the blood.
- The lack of markers, which specifically identify fetal cells is the crucial obstacle for the development of a reliable non-invasive prenatal diagnostic.
- The objective of this invention is the generation of antibodies, which allow the discrimination between fetal and adult erythroid cells and the unambiguous identification of fetal cells. Fetal cells recognized by these antibodies preferably should possess at least in part an intact cell nucleus, express the CD71 antigen and should miss the CD45 antigen in line with previously published results.
- Further, the object of the invention is the generation of monoclonal antibodies, which react specifically with fetal cells as well as a hybridoma cell line, which produces such antibodies. This object is solved by the antibody according to
embodiment 1, 7 or 10, the antigen according to claim 9 and the hybridoma cell according to embodiment 4 or 5. Further improvements of the antibodies, the hybridoma cell and the antigen are given in the embodiments 2-6, 8, and 11-16. - 1. Monoclonal antibody reacting with a surface antigen present on fetal red blood cells including their nucleated precursor cells, but not with surface antigens on adult erythroid cells.
- 2. Antibody according to embodiment 1, characterized in that it reacts with most or all fetal erythroid cells, which express the CD71 antigen but are negative for CD45 antigen expression.
- 3. Antibody according to embodiment 1 or 2, characterized in that it reacts with fetal erythroid cells but not with the CD71 antigen.
- 4. Hybridoma cell producing monoclonal antibodies according to one of the preceding embodiments.
- 5. Hybridoma cell as deposited under accession number DSM ACC 2666 on Jul. 13, 2004 at the Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH in Braunschweig, Germany.
- 6. Hybridoma cell according to embodiments 4 and 5.
- 7. Antibody expressed by the hybridoma cell according to one of embodiments 4 to 6.
- 8. Antibody according to embodiment 7 and one of embodiments 1 to 3.
- 9. Surface antigen on fetal red blood cells recognized by a monoclonal antibody as characterized in one of embodiments 1 to 3 and 7 to 8.
- 10. Antibody characterized in that it recognizes or binds specifically to a surface antigen according to embodiment 9.
- 11. Use of a monoclonal antibody according to one of embodiments 1 to 3, 7, 8 or 10 for the detection and identification of fetal cells in a sample.
- 12. Use according to the preceding embodiment for the detection and identification of fetal cells in a sample of maternal blood.
- 13. Method for detection or identification of fetal cells in a sample, characterized by labeling said fetal cells by an antibody according to one of embodiments 1 to 3, 7, 8, or 10.
- 14. Method according to the preceding embodiment, characterized in that the sample is maternal blood or a sample of maternal blood.
- 15. Use of a method according to
embodiments 13 or 14 for the detection of chromosomal and/or genetic aberrations, defects and/or variants in the fetal cells detected and identified by a method according to embodiment 13 to 14, characterized in that said fetal cells are subsequent to the detection and identification analyzed for a chromosomal and/or genetic aberration, defects and/or variant. - 16. Use or method according to one of embodiments 11 to 15, characterized in that cells binding the monoclonal antibody are separated by flow cytometry, solid phase separation, immunomagnetic bead separation, panning on plastic surfaces, or the like.
- For the purpose of the present invention 5 mice have been immunized with isolated erythroid cells from cord blood (CD71+, CD45−), which carried the “i” antigen as defined by the autoantibody described in
DE 100 35 433 A1. The immunization with these cells opens the possibility that besides antibodies against the “i” antigen also antibodies with specificities against new markers could be generated, which could be used to identify erythroid precursor cells. The spleen cells of the immunized mice were fused with a myeloma cell line to produce hybridomas according to standard procedures (Schetters H, Production of Monoclonal Antibodies, in: Methods of Immunological Analysis, Masseyeff R F, Albert W H and Staines N A (Eds.) Vol. 2, Ch. 4.3, 230-245, VCH Weinheim, 1993). -
FIG. 1A is a diagram of the light scatter properties of erythroid precursor cells.FIG. 1B is a diagram of fluorescence properties of the cells in region R1 and labeled with CD71-antibody and dye LDS751 labeling all nuclei.FIG. 1C is a diagram of fluorescence properties of cells in region R2 incubated with CD71 antibodies.FIG. 1D is a diagram of fluorescence properties of the cells in region R2. -
FIG. 2 is a graph showing the absorption of monoclonal antibodies 4B8 and 4B9 with adult erythrocytes, followed by the determination of their binding capability on cord blood cells. -
FIG. 3A is histogram showing unstained, negative cord blood cells marked as “unlabeled” and cord blood cells incubated with labeled antibodies 4B8 and 4B9.FIG. 3B is a histogram of the adult blood cells showing the same fluorescence intensity (x-axes), whether they are incubated as antibodies, 4B8, 4B9, or with no antibodies. - FIG. 4A1-4B2 shows the immunofluorescent and immunoenzymatic analyses of fetal blood cells. FIG. 4A1 and FIG. 4B1 show the original fluorescence picture and FIG. 4A2 and FIG. 4B2 show schematic drawings of FIG. 4A1 and FIG. 4B1, respectively.
- In detail, mice were immunized with flow sorted human cord blood cells (CD71+, antigen-i+, CD19− and CD45−). Hybridoma supernatants were screened on pooled mononuclear cord blood cells, whereas the corresponding amount of erythroid precursors was determined by cytochemical staining of blood smears. For the hybridoma screening a six-parameter flow cytometric analysis (four colours, forward and side scatter) was set up for the simultaneous identification of erythroid precursor cells, leukocytes, enucleated erythrocytes and for antibodies reacting specifically with fetal cells. Furthermore, immunohistochemical analyses have been performed with fetal blood smears and fetal liver sections from the 6th up to 38th week of gestation as well as with adult blood, normal adult bone marrow and adult erythrocytes as controls.
- A clone (accession number DSM ACC 2666 at the Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH (DSMZ)) with specificity for a surface antigen exclusively expressed on fetal erythroid cells has been identified. The new antibody showed unaltered binding to erythroid cells from fetal blood of early times of gestation (6th week) up to childbirth. Moreover, detailed examinations showed no surface reactivity with adult erythrocytes, erythroblasts or lymphatic and myeloid cells. This antibody did not react with cells of fetal haemolymphatic organs.
- The investigation showed that the new monoclonal antibody binds specifically fetal erythroid cells and thus can differentiate between fetal and adult red blood cells. Because of the expression of this fetal antigen in early stages of gestation a noninvasive prenatal diagnostic may be feasible. This antibody can be applied for different enrichment techniques and/or for the identification of fetal erythroid cells.
- Screening for Hybridomas Producing Antibodies Reacting Specifically with Fetal NRBCs
- Since several thousand antibody producing hybridomas have to be screened to find a suitable clone a procedure has been set up permitting a high through-put whilst maintaining the required specificity. A six-parameter analysis (4 fluorescence channels, forward and side scatter) has been established, which enabled the simultaneous identification of erythroid precursor cells, the differentiation of leukocytes from enucleated erythrocytes and the identification of new antibodies in a single step. The analysed cells have been stained with a nucleic acid dye (LDS751, Molecular Probes, cat# 7595) and have been incubated with antibodies of the cloned hybridomas. These antibodies were subjected to a reaction with an antibody directed against them, which was labeled with a fluorescent dye (FITC) (Goat anti mouse IgG (H+L)-FITC, Caltag Laboratories, cat# M35001). In later experiments for antibody characterization the antibodies have been labeled directly with FITC.
- The identification of the erythroid precursor cells is possible due to their light scatter characteristics and by their binding of phycoerythrin labeled CD71 specific antibodies (CD71 PE, Diatec, cat#3212). Leukocytes could be discerned by their binding to allophycocyanin labeled CD45 specific antibodies (CD45 APC, BD Pharmingen, cat#555485). Nucleated and enucleated erythroid cells can be distinguished by their binding or absence of binding of the nucleic acid dye. With this procedure it is possible to identify antibodies binding to the intended target cells, i.e. fetal NRBCs, without cross-reaction towards adult erythrocytes or leukocytes (
FIG. 1 ). - Exclusion of Antibodies Reacting with Antigens on Adult Erythrocytes Including Common Blood Group Antigens
- Blood group antigens can be found on adult erythrocytes and their precursors in large amounts. Therefore, they might induce a major immune response when used as antigens. Antibodies against these blood group antigens are not suitable for the identification of fetal cells. In order to exclude antibodies binding to antigens on adult erythrocytes including blood group antigens, their binding specificity towards fetal cells is investigated after absorption on erythrocytes. Erythrocyte with the blood group AB Rh+ have been harvested and stabilized with a reagent supplied by Meridian Diagnostics Europe, Bad Homburg. The antibodies under investigation have been incubated with increasing numbers of erythrocytes and tested before and afterwards for their binding activity for target cells. Reactivity of antibodies towards blood group antigens was thought to be absent, when the intensity of the binding to CD71+, CD45− nucleated erythroid precursor cells was unchanged after the incubation with the erythrocytes (
FIG. 2 ). Antibodies selected that way must not react with adult blood cells to enable the correct identification of fetal erythroid precursor cells (FIG. 3 ). - Hybridoma clone producing a monoclonal antibody of the IgM isotype showing the required binding characteristics in the screening procedure could be identified. It has the designation 4B9 and was deposited by the applicant of the present patent or patent application on Jul. 13, 2004 at the Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH (DSMZ, Braunschweig) under the accession number DSM ACC 2666. A second antibody 4B8 recognizing the same epitope is mentioned in
FIGS. 2 and 3 . - Fetal and adult erythroblasts strongly and specifically express glycophorin-A and, therefore, can be identified through this marker protein. The binding of the monoclonal antibody to these cells was visualized by an immunofluorescence double stain.
-
- 1 Fix cytospins or frozen tissue sections in acetone for 10 min
- 2 Dry for 5 min
- 3 Apply monoclonal antibody against glycophorin-A, DAKO M0819 diluted 1:100 in phosphate buffered saline (PBS) containing 1% bovine serum albumin (BSA) for 60 min
- 4 Rinse with PBS
- 5 Apply goat anti-mouse antibody F(ab) fragment, Alexa Fluor 488 (Molecular Probes A21044), green, diluted 1:100 in PBS for 60 min
- 6 Rinse with PBS
- 7 Apply monoclonal antibody 4B9 (hybridoma supernatant) for 60 min
- 8 Rinse with PBS
- 9 Apply goat anti-mouse IgM, Alexa Fluor 594 (Molecular Probes A-21044), red, for 60 min
- 10 Rinse with PBS
- 11 Stain cell nuclei with DAPI (Molecular Probes), blue, diluted 1:300 in PBS for 3 min
- 12 Rinse with PBS
- 13 Cover with fluorescence medium (S3023, DAKO)
- 14 Visualize with “Universalmikroskop Axioplan”, Carl Zeiss, using filter sets 02, 10 and 15 and photograph with a digital camera system, e.g. Visitron Systems GmbH
- PBS: 8 g NaCl, 1.3 g Na2HPO4, 4 g NaH2PO4 in 1 l H2O, pH 7.4
- An immunoenzymatic method has also been used:
-
- 1 Fix cytospins or frozen tissue slices in acetone for 10 min
- 2 Dry for 5 min
- 3 Incubate with monoclonal antibody 4B9 (hybridoma supernatant) for 30 min
- 4 Rinse with Tris buffered saline (TBS)
- 5 Incubate with APAAP complex (D0651, DAKO), diluted 1:25 in TBS/HS (inactivated human serum) for 30 min
- 6 Rinse with TBS
- 7 Repeat steps 5-7 twice for 10 min each
- 8 Rinse with TBS
- 9 Develop slides with substrate
- i. Prepare solution A: Mix 18 ml 0.2 mol/l 2-amino-2methyl-1,3-propandiol with 50 ml 0.05 mol/l Tris buffer, pH 9.7 and 600 mg NaCl. Add 28 mg levamisol.
- ii. Prepare solution B: Dissolve 35 mg naphthol AS-bi-phosphate in 0.42 ml N,N-dimethylformamide.
- iii. Prepare solution C: Mix 0.14 ml 5% New Fuchsin with 0.35 freshly prepared 4% sodium nitrite. Stir for 60 sec.
- iv. Mix solution A with solution B, then add solution C. Adjust the pH to 8.7. Mix, filter and apply to slides.
- v. Incubate for 10-20 min at room temperature.
- vi. Rinse with tap water.
- vii. Counter stain with Meyer's acid Haemalaun for 5 min.
- viii. “Blue” in tap water for 10 min and cover with Kaiser's glycerol gelatine.
- TBS (Tris buffered saline): Dissolve 43.33 g NaCl and 39.40 g Tris-HCl in 5 l H2O dest. Adjust pH to 7.4 with NaOH.
- TBS/HS: 9 parts TBS+1 part inactivated human serum
- Monoclonal antibody of identical isotype or murine hyper-immune serum.
- Exclusion of Antibodies Reacting with CD71
- Antibodies generated with the immunization strategy used may be directed against CD71. To exclude these antibodies, analyses were performed that show whether CD71-antibodies compete for the same binding site. Biotinylated antibody 4B8 was preincubated with mononuclear cells from cord blood. Then unlabeled CD71-specific antibody (Anti-CD71, Clone DF1513, DPC Biermann, Bad Nauheim, Germany) was added. After streptavidin-DTAF-labeling it was analyzed by flow cytometry whether CD71-antibodies had replaced the antibody 4B8. As a positive control sample for this competition experiment, unlabeled antibody 4B8 was added instead of CD71. These analyses showed that antibodies 4B8 and CD71 do not compete for the same epitope whereas the addition of unlabeled antibody 4B8 had diminished the signal.
-
-
- The 4B9-reactive antigen was expressed on the surface of fetal erythroblasts. This could be demonstrated with fetal cells from the 6. up to the 38th week of gestation. In
FIG. 4 the antibody 4B9 recognised all glycophorin-A positive fetal erythroblasts. - Erythroblasts in normal adult bone marrow were negative for 4B9. In contrast, all erythropoietic cells were positive for glycophorin-A. Only in 1 of 32 cases a intracellular granular expression in the cytoplasm of early basophile erythroblasts was seen.
- The 4B9 reactive antigen was not found on adult and fetal liver hepatocytes. Kupffer cells, macrophages, endothelial and sinusoidal cells were also negative.
- A detailed analysis of haemolymphatic cells in adults showed the absence of reactivity in lymphatic and myeloic cells.
- All haemolymphatic organs of the fetus were negative. This applies for lymphatic as well as myeloic cells.
- The 4B9-reactive antigen was expressed on the surface of fetal erythroblasts. This could be demonstrated with fetal cells from the 6. up to the 38th week of gestation. In
-
TABLE 1 Detailed results of the reactivity of the monoclonal antibody 4B9 Adult Fetal Cell or tissue (n positive/n samples) Granulopoiesis Neutrophils Segmented 0/8 0/14 Rodforms 0/8 0/14 Metamyelocytes 0/8 0/14 Myelocytes 0/8 0/14 Promyelocytes 0/8 0/14 Eosinophils Rodforms 0/8 0/14 Metamyelocytes 0/8 0/14 Myelocytes 0/8 0/14 Promyelocytes 0/8 0/14 Basophils 0/8 0/14 Monocytes Mature monocytes 0/8 0/14 Promonocytes 0/8 0/14 Myelocyte 0/8 0/14 Macrophages 0/8 0/14 Thrombocytopoieses Platelets 0/8 0/14 Megakaryocytes 0/8 0/14 Megakaryoblasts 0/8 0/14 Erythrocytopoiesis Erythrocytes 0/8 14/14 Reticulocytes 0/8 10/10 Normoblasts 0/8 4/4 Euchrom. Erythroblasts 1/32 5/5 Polychrom. Erythroblasts 0/8 10/10 Basophilic erythroblasts 0/8 4/4 Proerythroblasts 0/8 4/4 Lymphocytopoiesis B lymphocytes 0/8 0/14 Plasma cells 0/8 0/14 T lymphocytes 0/8 0/14 Hepatocytes 0/8 0/4 Kupffer cells 0/8 0/4 Other hepatic cells 0/8 0/8 - In the following,
FIGS. 1 to 4 are described in detail -
FIG. 1 - Mononuclear cord blood cells were stained with labeled antibodies (anti CD45, anti CD71 and the antibody under investigation, 4B9) and a DNA dye. Antibody binding was measured with a flow cytometer.
-
- a) This
FIG. 1 a shows a diagram with the light scatter properties of erythroid precursor cells. For further characterization, the cells characterized by means of their light scatter properties in region R1 were used. - b)
FIG. 1 b shows a diagram of fluorescence properties of the cells in region R1 and labeled with CD71-antibody and dye LDS751 labeling all nuclei. Region R2 encloses nucleated cells which express or do not express CD71 antigen. - c)
FIG. 1 c shows a diagram of fluorescence properties of the cells in region R2 incubated with CD71 antibodies and CD45 antibodies. The cells in region R3 express CD71 antigen but not CD45 antigen. This diagram demonstrates the differentiation between CD71 positive nucleated erythroid cells (Region R3) and CD45 positive leukocytes. - d)
FIG. 1 d shows a diagram of fluorescence properties of the cells in region R2. The cells in region R4 express CD71 antigen and bind to the 4B9 antibody. Thus, antibody 4B9 binds preferentially to CD71 positive cells, which are CD45 negative.
- a) This
-
FIG. 2 -
FIG. 2 discloses absorption of monoclonal antibodies 4B8 and 4B9 with adult erythrocytes, followed by the determination of their binding capability on cord blood cells. It is shown that neither 4B8 antibody nor 4B9 antibody is absorbed by adult red blood cells. For positive and negative controls antibodies against CD71 and glycophorin A were used. -
FIG. 3 - Flow cytometric investigation of the binding of the monoclonal antibodies 4B8 and 4B9 on cord blood cells and adult blood cells (x-axis: fluorescence intensity).
-
- a) This histogram shows unstained, negative cord blood cells marked as “unlabeled” and cord blood cells incubated with labeled antibodies 4B8 (marked as 4B8) and 4B9 (marked as 4B9). This demonstrates that cord blood cells are stained by antibodies 4B8 and 4B9.
- b) In this figure, adult blood cells show the same fluorescence intensity (x-axes), whether they are incubated with antibodies 4B8 (“4B8”) or 4B9 (“4B9”) or with no antibody (“unlabeled”). Thus, antibodies 4B8 and 4B9 do not bind to adult blood cells.
-
FIG. 4 - Immunofluorescent and immunoenzymatic analyses of fetal blood cells.
- A) and B) Glycophorin A-positive (marked with “G”) fetal erythropoietic cells express the 4B9 antigen (fluorescent, filled black regions in the cells schematically drawn in FIGS. 4A2 and 4B2). Cell nuclei are stained with DAPI and marked with “B” in FIG. 4A2 and FIG. 4B2. Obviously, nucleated and enucleated red blood cells are positive for the 4B9 antigen. FIG. 4A1 and FIG. 4B1 show the original fluorescence picture and FIG. 4A2 and FIG. 4B2 show schematic drawings of FIG. 4A1 and FIG. 4B1, respectively.
Claims (16)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/825,516 US20160039932A1 (en) | 2004-03-31 | 2015-08-13 | Monoclonal antibodies with specificity for fetal erythroid cells |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04007811 | 2004-03-31 | ||
EP04007811.5 | 2004-03-31 | ||
PCT/EP2005/003371 WO2005100401A2 (en) | 2004-03-31 | 2005-03-31 | Monoclonal antibodies with specificity for fetal erythroid cells |
US59951207A | 2007-05-29 | 2007-05-29 | |
US12/979,535 US8536312B2 (en) | 2004-03-31 | 2010-12-28 | Monoclonal antibodies with specificity for fetal erythroid cells |
US14/028,027 US9194871B2 (en) | 2004-03-31 | 2013-09-16 | Monoclonal antibodies with specificity for fetal erythroid cells |
US14/825,516 US20160039932A1 (en) | 2004-03-31 | 2015-08-13 | Monoclonal antibodies with specificity for fetal erythroid cells |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/028,027 Division US9194871B2 (en) | 2004-03-31 | 2013-09-16 | Monoclonal antibodies with specificity for fetal erythroid cells |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160039932A1 true US20160039932A1 (en) | 2016-02-11 |
Family
ID=35150543
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/599,512 Active 2027-05-04 US7858757B2 (en) | 2004-03-31 | 2005-03-31 | Monoclonal antibodies with specificity for fetal erythroid cells |
US12/979,535 Active 2025-08-17 US8536312B2 (en) | 2004-03-31 | 2010-12-28 | Monoclonal antibodies with specificity for fetal erythroid cells |
US14/028,027 Active US9194871B2 (en) | 2004-03-31 | 2013-09-16 | Monoclonal antibodies with specificity for fetal erythroid cells |
US14/825,516 Abandoned US20160039932A1 (en) | 2004-03-31 | 2015-08-13 | Monoclonal antibodies with specificity for fetal erythroid cells |
US14/882,995 Active US9453841B2 (en) | 2004-03-31 | 2015-10-14 | Monoclonal antibodies with specificity for fetal erythroid cells |
US17/989,895 Pending US20230324383A1 (en) | 2004-03-31 | 2022-11-18 | Monoclonal antibodies with specificity for fetal erythroid cells |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/599,512 Active 2027-05-04 US7858757B2 (en) | 2004-03-31 | 2005-03-31 | Monoclonal antibodies with specificity for fetal erythroid cells |
US12/979,535 Active 2025-08-17 US8536312B2 (en) | 2004-03-31 | 2010-12-28 | Monoclonal antibodies with specificity for fetal erythroid cells |
US14/028,027 Active US9194871B2 (en) | 2004-03-31 | 2013-09-16 | Monoclonal antibodies with specificity for fetal erythroid cells |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/882,995 Active US9453841B2 (en) | 2004-03-31 | 2015-10-14 | Monoclonal antibodies with specificity for fetal erythroid cells |
US17/989,895 Pending US20230324383A1 (en) | 2004-03-31 | 2022-11-18 | Monoclonal antibodies with specificity for fetal erythroid cells |
Country Status (9)
Country | Link |
---|---|
US (6) | US7858757B2 (en) |
EP (1) | EP1732951B1 (en) |
JP (1) | JP4756032B2 (en) |
AT (1) | ATE450549T1 (en) |
AU (1) | AU2005233254B2 (en) |
CA (1) | CA2561830C (en) |
DE (1) | DE602005018028D1 (en) |
ES (1) | ES2337702T3 (en) |
WO (1) | WO2005100401A2 (en) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4756032B2 (en) * | 2004-03-31 | 2011-08-24 | アトナーゲン アクチエンゲゼルシャフト | Monoclonal antibody with specificity for fetal red blood cells |
US9424392B2 (en) | 2005-11-26 | 2016-08-23 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
US11111544B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US10081839B2 (en) | 2005-07-29 | 2018-09-25 | Natera, Inc | System and method for cleaning noisy genetic data and determining chromosome copy number |
US10083273B2 (en) | 2005-07-29 | 2018-09-25 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US11111543B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
DE102006062619B4 (en) * | 2006-12-29 | 2012-04-26 | Medion Diagnostics Ag | Method for the determination of minor cell populations in heterogeneous cell populations |
CA2731991C (en) | 2008-08-04 | 2021-06-08 | Gene Security Network, Inc. | Methods for allele calling and ploidy calling |
EP2473638B1 (en) | 2009-09-30 | 2017-08-09 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
WO2011146632A1 (en) | 2010-05-18 | 2011-11-24 | Gene Security Network Inc. | Methods for non-invasive prenatal ploidy calling |
US11408031B2 (en) | 2010-05-18 | 2022-08-09 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
US11332785B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11332793B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11326208B2 (en) | 2010-05-18 | 2022-05-10 | Natera, Inc. | Methods for nested PCR amplification of cell-free DNA |
US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11339429B2 (en) | 2010-05-18 | 2022-05-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
SI2646470T1 (en) | 2010-11-30 | 2017-05-31 | F. Hoffmann-La Roche Ag | Low affinity anti-transferrin receptor antibodies and their use to transfer therapeutic scfv across the blood brain barrier |
JP6328934B2 (en) | 2010-12-22 | 2018-05-23 | ナテラ, インコーポレイテッド | Noninvasive prenatal testing |
AU2011358564B9 (en) | 2011-02-09 | 2017-07-13 | Natera, Inc | Methods for non-invasive prenatal ploidy calling |
US10466160B2 (en) | 2011-08-01 | 2019-11-05 | Celsee Diagnostics, Inc. | System and method for retrieving and analyzing particles |
US9174216B2 (en) | 2013-03-13 | 2015-11-03 | DeNovo Science, Inc. | System for capturing and analyzing cells |
US9404864B2 (en) | 2013-03-13 | 2016-08-02 | Denovo Sciences, Inc. | System for imaging captured cells |
US9103754B2 (en) | 2011-08-01 | 2015-08-11 | Denovo Sciences, Inc. | Cell capture system and method of use |
US20130122492A1 (en) | 2011-11-14 | 2013-05-16 | Kellbenx Inc. | Detection, isolation and analysis of rare cells in biological fluids |
EP4008270A1 (en) | 2012-06-22 | 2022-06-08 | Preprogen LLC | Method for obtaining fetal cells and fetal cellular components |
US9752181B2 (en) | 2013-01-26 | 2017-09-05 | Denovo Sciences, Inc. | System and method for capturing and analyzing cells |
US9707562B2 (en) | 2013-03-13 | 2017-07-18 | Denovo Sciences, Inc. | System for capturing and analyzing cells |
US9856535B2 (en) | 2013-05-31 | 2018-01-02 | Denovo Sciences, Inc. | System for isolating cells |
US10391490B2 (en) | 2013-05-31 | 2019-08-27 | Celsee Diagnostics, Inc. | System and method for isolating and analyzing cells |
US10262755B2 (en) | 2014-04-21 | 2019-04-16 | Natera, Inc. | Detecting cancer mutations and aneuploidy in chromosomal segments |
WO2015048535A1 (en) | 2013-09-27 | 2015-04-02 | Natera, Inc. | Prenatal diagnostic resting standards |
US10577655B2 (en) | 2013-09-27 | 2020-03-03 | Natera, Inc. | Cell free DNA diagnostic testing standards |
CN113774132A (en) | 2014-04-21 | 2021-12-10 | 纳特拉公司 | Detection of mutations and ploidy in chromosomal segments |
US20160130553A1 (en) * | 2014-05-15 | 2016-05-12 | Kellbenx Incorporated | PREPARATION OF FETAL NUCLEATED RED BLOOD CELLS (NRBCs) FOR DIAGNOSTIC TESTING |
JP2017521091A (en) * | 2014-05-15 | 2017-08-03 | ケルベンクス インコーポレイテッド | Preparation of fetal nucleated red blood cells (NRBC) for diagnostic tests |
EP3179248A4 (en) * | 2014-08-05 | 2017-06-14 | Fujifilm Corporation | Method for separating nucleated red blood cells |
US11479812B2 (en) | 2015-05-11 | 2022-10-25 | Natera, Inc. | Methods and compositions for determining ploidy |
WO2018067517A1 (en) | 2016-10-04 | 2018-04-12 | Natera, Inc. | Methods for characterizing copy number variation using proximity-litigation sequencing |
US10011870B2 (en) | 2016-12-07 | 2018-07-03 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
JP6234542B1 (en) | 2016-12-27 | 2017-11-22 | 株式会社 TL Genomics | Method for obtaining chromosomal DNA derived from fetal cells |
CA3049139A1 (en) | 2017-02-21 | 2018-08-30 | Natera, Inc. | Compositions, methods, and kits for isolating nucleic acids |
JP6980904B2 (en) | 2017-08-29 | 2021-12-15 | バイオ−ラッド ラボラトリーズ インコーポレイテッド | Systems and methods for isolating and analyzing cells |
WO2019078277A1 (en) | 2017-10-19 | 2019-04-25 | 株式会社 TL Genomics | Chip for cell classification |
US10946380B2 (en) * | 2018-01-19 | 2021-03-16 | International Business Machines Corporation | Microfluidic chips for particle purification and fractionation |
US11525159B2 (en) | 2018-07-03 | 2022-12-13 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
US10633693B1 (en) | 2019-04-16 | 2020-04-28 | Celsee Diagnostics, Inc. | System and method for leakage control in a particle capture system |
US20230258663A9 (en) | 2019-05-02 | 2023-08-17 | Kellbenx Incorporated | Filtration-based methods for preparing fetal nucleated red blood cells (nrbcs) for diagnostic testing |
US11273439B2 (en) | 2019-05-07 | 2022-03-15 | Bio-Rad Laboratories, Inc. | System and method for target material retrieval from microwells |
US11578322B2 (en) | 2019-05-07 | 2023-02-14 | Bio-Rad Laboratories, Inc. | System and method for automated single cell processing |
KR20220033484A (en) | 2019-06-14 | 2022-03-16 | 바이오 래드 래버러토리스 인코오포레이티드 | Systems and Methods for Automated Single Cell Processing and Analysis |
US11504719B2 (en) | 2020-03-12 | 2022-11-22 | Bio-Rad Laboratories, Inc. | System and method for receiving and delivering a fluid for sample processing |
US11827702B2 (en) | 2021-09-01 | 2023-11-28 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10035433C2 (en) * | 2000-07-20 | 2002-07-18 | Tuma Wolfgang | Gentle high enrichment of fetal cells from peripheral blood and use of the same |
ITRM20010322A1 (en) | 2001-06-08 | 2002-12-09 | Consiglio Nazionale Ricerche | NON-IVASIVE METHOD ON MATERNAL BLOOD FOR THE SCREENING AND DIAGNOSIS OF FETAL ANEUPLOIDIES. |
JP4756032B2 (en) * | 2004-03-31 | 2011-08-24 | アトナーゲン アクチエンゲゼルシャフト | Monoclonal antibody with specificity for fetal red blood cells |
-
2005
- 2005-03-31 JP JP2007505500A patent/JP4756032B2/en active Active
- 2005-03-31 AT AT05736009T patent/ATE450549T1/en active
- 2005-03-31 EP EP05736009A patent/EP1732951B1/en active Active
- 2005-03-31 AU AU2005233254A patent/AU2005233254B2/en active Active
- 2005-03-31 ES ES05736009T patent/ES2337702T3/en active Active
- 2005-03-31 CA CA2561830A patent/CA2561830C/en active Active
- 2005-03-31 DE DE602005018028T patent/DE602005018028D1/en active Active
- 2005-03-31 WO PCT/EP2005/003371 patent/WO2005100401A2/en active Application Filing
- 2005-03-31 US US10/599,512 patent/US7858757B2/en active Active
-
2010
- 2010-12-28 US US12/979,535 patent/US8536312B2/en active Active
-
2013
- 2013-09-16 US US14/028,027 patent/US9194871B2/en active Active
-
2015
- 2015-08-13 US US14/825,516 patent/US20160039932A1/en not_active Abandoned
- 2015-10-14 US US14/882,995 patent/US9453841B2/en active Active
-
2022
- 2022-11-18 US US17/989,895 patent/US20230324383A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2561830C (en) | 2013-05-21 |
US20070275418A1 (en) | 2007-11-29 |
EP1732951A2 (en) | 2006-12-20 |
AU2005233254A1 (en) | 2005-10-27 |
JP4756032B2 (en) | 2011-08-24 |
US20140154704A1 (en) | 2014-06-05 |
US20110129916A1 (en) | 2011-06-02 |
AU2005233254B2 (en) | 2011-11-24 |
US9194871B2 (en) | 2015-11-24 |
WO2005100401A2 (en) | 2005-10-27 |
ATE450549T1 (en) | 2009-12-15 |
US7858757B2 (en) | 2010-12-28 |
WO2005100401A3 (en) | 2006-06-15 |
US9453841B2 (en) | 2016-09-27 |
US8536312B2 (en) | 2013-09-17 |
DE602005018028D1 (en) | 2010-01-14 |
US20230324383A1 (en) | 2023-10-12 |
ES2337702T3 (en) | 2010-04-28 |
EP1732951B1 (en) | 2009-12-02 |
US20160084837A1 (en) | 2016-03-24 |
CA2561830A1 (en) | 2005-10-27 |
JP2007530629A (en) | 2007-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230324383A1 (en) | Monoclonal antibodies with specificity for fetal erythroid cells | |
Lewis et al. | Rare event selection of fetal nucleated erythrocytes in maternal blood by flow cytometry | |
Janossy et al. | Immuno-histological diagnosis of lymphoproliferative diseases by selected combinations of antisera and monoclonal antibodies | |
Van Der Schoot et al. | Monoclonal antibodies against myeloperoxidase are valuable immunological reagents for the diagnosis of acute myeloid leukaemia | |
US20070269835A1 (en) | Reagent for determining laminin 5 antigen in biological sample and assay method | |
EP1423706B1 (en) | Determination and quantification of red blood cell populations in samples | |
Garner et al. | A rapid one‐stage whole‐blood HPA‐1a phenotyping assay using a recombinant monoclonal IgG1 anti‐HPA‐1a | |
EP0412700B1 (en) | Method for isolating fetal cytotrophoblast cells | |
JP2004504818A (en) | Mild high enrichment of fetal cells from peripheral blood and its use | |
Hadji-Azimi et al. | B-lymphocyte populations in Xenopus laevis | |
Van Heerde et al. | Non‐Hodgkin's Lymphoma. Immunohistochemical and electron microscopical findings in relation to lightmicroscopy A study of 74 cases | |
Cordier et al. | Flow cytometry sorting of unlabelled epidermal Langerhans cells using forward and orthogonal light scatter properties | |
WO1999024832A1 (en) | Distinguishing of viable, early apoptotic and necrotic cells | |
EP0232706A2 (en) | Blood group antigen panel | |
Jansson et al. | Classification of acute leukaemia by light and electron microscope cytochemistry | |
US6074833A (en) | Osteoblast and fibroblast antigen and antibodies recognizing it | |
CA2949324A1 (en) | Method and enzyme solution for flow-cytometric detection of light chain restriction | |
EP1500934A1 (en) | A method for determining a risk of atherosclerosis or future development of atherosclerotic complications | |
Christensson et al. | Correlation of immunophenotype to morphology in unfavourable non‐Hodgkin lymphoma | |
Kamps et al. | Halbe H. Spanjer, and Sibrand Poppema Departments of Pediatrics and Pathology, University of Groningen, Groningen, The Netherlands | |
JOHANSSON | CORRELATION OF IMMUNOPHENOTYPE TO MORPHOLOGY IN UNFAVOURABLE NON-HODGKIN LYMPHOMA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ADNAGEN AG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HOLLMANN, CHRISTIANE;ALBERT, WINFRIED;ZIMMERMANN, SILKE;AND OTHERS;SIGNING DATES FROM 20061026 TO 20061123;REEL/FRAME:038266/0080 Owner name: KELLBENX INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALERE DIAGNOSTICS GMBH;REEL/FRAME:038266/0234 Effective date: 20150422 Owner name: ALERE DIAGNOSTICS GMBH, GERMANY Free format text: CHANGE OF NAME;ASSIGNOR:ADNAGEN GMBH;REEL/FRAME:038427/0077 Effective date: 20150318 Owner name: ADNAGEN GMBH, GERMANY Free format text: CHANGE OF NAME;ASSIGNOR:ADNAGEN AG;REEL/FRAME:038427/0048 Effective date: 20110419 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |